Endometriosis affects roughly 190 million women worldwide. Current treatments are either hormonal (with all the side effects that entails) or surgical (which provides temporary relief but doesn’t cure the disease). In March 2026, the FDA cleared an investigational new drug application for something different: the first non-hormonal targeted peptide therapeutic designed to eliminate endometriosis lesions.
This article covers what’s in the research pipeline, what peptides are being used off-label now, and what the science actually supports vs. what’s speculative.
In March 2026, the FDA cleared the Investigational New Drug (IND) application for ENDO-205, developed by EndoCyclic Therapeutics. According to the company, ENDO-205 is the first therapy in development designed to eliminate endometriosis lesions and address associated symptoms including pain and systemic complications.
ENDO-205 is a non-hormonal peptide therapeutic — a significant distinction. Current endometriosis treatments (oral contraceptives, GnRH agonists/antagonists) work by suppressing ovarian function, which reduces symptoms but creates its own set of problems: bone density loss, menopausal symptoms, and the inability to conceive during treatment. A targeted peptide that eliminates lesions without hormonal suppression would be a paradigm shift.
EndoCyclic is planning Phase 1 clinical studies in healthy premenopausal women. This is early-stage research — clinical availability is likely 5-8 years away at minimum — but the approach represents a fundamentally different strategy than anything currently available.
ENDO-205 didn’t emerge from nothing. Researchers have been exploring peptide-based approaches to endometriosis for over a decade.
In 2014, researchers identified an endometriosis-targeting peptide called z13 using phage display technology. When z13 was linked to an apoptosis-inducing peptide and administered into the peritoneum of baboons with endometriosis, cells in lesions selectively underwent apoptosis with no effect on neighboring organs. This proved that peptide-guided targeting of endometriosis lesions was possible.
In 2024, researchers developed an injectable magnetic hydrogel incorporating anti-inflammatory peptides for endometriosis treatment. In animal studies, the system achieved a 90% reduction in endometriotic lesion volume and significantly decreased inflammatory markers.
These preclinical successes set the stage for ENDO-205’s clinical translation.
While targeted endometriosis peptides are still years from clinical availability, some women and their providers are exploring existing peptides for symptom management:
BPC-157’s anti-inflammatory and tissue-healing properties make it theoretically relevant to endometriosis-associated pain. No clinical studies exist for this specific indication. Use is based on clinical observation and extrapolation from BPC-157’s broader anti-inflammatory data. Note: as of April 2026, BPC-157 is not eligible for 503A compounding; no licensed U.S. compounding pathway currently exists.
Emerging research suggests GLP-1 receptor agonists (semaglutide, tirzepatide) have anti-inflammatory effects beyond weight management. For women with endometriosis-associated metabolic disruption, these may address both the weight gain and the systemic inflammation that drives disease progression.
Chronic pain conditions like endometriosis frequently co-occur with anxiety and mood disruption. Selank’s anxiolytic and nootropic effects may help manage the psychological burden of living with endometriosis.
Not yet approved, but ENDO-205 by EndoCyclic Therapeutics received FDA IND clearance in March 2026. It's described as the first non-hormonal targeted peptide designed to eliminate endometriosis lesions. Phase 1 trials in healthy premenopausal women are being planned. This is early-stage — clinical availability is likely years away.
No clinical studies have examined BPC-157 for endometriosis specifically. However, BPC-157's anti-inflammatory and tissue-healing properties are theoretically relevant. Some practitioners include it in broader pain management protocols. This is off-label use based on mechanistic reasoning, not clinical evidence.
GLP-1 receptor agonists may help with endometriosis-associated weight gain and inflammation. Selank may address anxiety and mood disruption common with chronic pain conditions. BPC-157 is used anecdotally for pelvic pain. None of these are FDA-approved for endometriosis.
Endometriosis affects approximately 10-15% of women of reproductive age — roughly 190 million women worldwide. It takes an average of 7-10 years from symptom onset to diagnosis. The economic burden in the U.S. alone exceeds $22 billion annually in direct and indirect costs.